

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

| | | | |
|------|----|--------|--|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | AUG 06 | CAS REGISTRY enhanced with new experimental property tags |
| NEWS | 3 | AUG 06 | FSTA enhanced with new thesaurus edition |
| NEWS | 4 | AUG 13 | CA/CAplus enhanced with additional kind codes for granted patents |
| NEWS | 5 | AUG 20 | CA/CAplus enhanced with CAS indexing in pre-1907 records |
| NEWS | 6 | AUG 27 | Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB |
| NEWS | 7 | AUG 27 | USPATOLD now available on STN |
| NEWS | 8 | AUG 28 | CAS REGISTRY enhanced with additional experimental spectral property data |
| NEWS | 9 | SEP 07 | STN AnaVist, Version 2.0, now available with Derwent World Patents Index |
| NEWS | 10 | SEP 13 | FORIS renamed to SOFIS |
| NEWS | 11 | SEP 13 | INPADOCDB enhanced with monthly SDI frequency |
| NEWS | 12 | SEP 17 | CA/CAplus enhanced with printed CA page images from 1967-1998 |
| NEWS | 13 | SEP 17 | CAplus coverage extended to include traditional medicine patents |
| NEWS | 14 | SEP 24 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS | 15 | OCT 02 | CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt |
| NEWS | 16 | OCT 19 | BEILSTEIN updated with new compounds |
| NEWS | 17 | NOV 15 | Derwent Indian patent publication number format enhanced |
| NEWS | 18 | NOV 19 | WPIX enhanced with XML display format |
| NEWS | 19 | NOV 30 | ICSD reloaded with enhancements |
| NEWS | 20 | DEC 04 | LINPADOCDB now available on STN |
| NEWS | 21 | DEC 14 | BEILSTEIN pricing structure to change |
| NEWS | 22 | DEC 17 | USPATOLD added to additional database clusters |
| NEWS | 23 | DEC 17 | IMSDRUGCONF removed from database clusters and STN |
| NEWS | 24 | DEC 17 | DGENE now includes more than 10 million sequences |
| NEWS | 25 | DEC 17 | TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment |
| NEWS | 26 | DEC 17 | MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary |
| NEWS | 27 | DEC 17 | CA/CAplus enhanced with new custom IPC display formats |
| NEWS | 28 | DEC 17 | STN Viewer enhanced with full-text patent content from USPATOLD |
| NEWS | 29 | JAN 02 | STN pricing information for 2008 now available |
| NEWS | 30 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS | 31 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS | 32 | JAN 28 | MARPAT searching enhanced |
| NEWS | 33 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS | 34 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |
| NEWS | 35 | JAN 28 | MEDLINE and LMEDLINE reloaded with enhancements |

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:24:28 ON 30 JAN 2008

FILE 'REGISTRY' ENTERED AT 18:24:38 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3
DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10552493.str
```



```
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14  
chain bonds :
```


6-10
ring bonds :
1-5 1-2 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :
1-5 1-2 6-10 10-11 10-14 11-12
exact bonds :
2-3 3-4 12-13 13-14
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9
isolated ring systems :
containing 1 : 10 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 18:25:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 146 TO 694
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 18:25:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 338 TO ITERATE

100.0% PROCESSED 338 ITERATIONS 86 ANSWERS
SEARCH TIME: 00.00.01

L3 86 SEA SSS FUL L1

| | | | |
|----------------------|--|------------|---------|
| => file caplus | | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | | ENTRY | SESSION |
| FULL ESTIMATED COST | | 178.36 | 178.57 |

FILE 'CAPLUS' ENTERED AT 18:25:17 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full
L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 DOCUMENT NUMBER: 2006:1093832 CAPLUS
 TITLE: Process for preparing heterocyclypyrolopyridines
 and their use as antagonists of corticotropin-releasing factor (CRF) receptors
 INVENTOR(S): Andreotti, Daniela; Bacchi, Sergio; Delpoggetto, Monica; Gelfi, Simone; Perboni, Alide; Ribecai, Arianna; Spada, Simone; Stabile, Paolo; Tampieri, Marsia
 PATENT ASSIGNEE(S): SB Pharma Puerto Rico Inc, USA; Neurocrine Biosciences, Inc.
 SOURCE: PCT Int. Appl. 42pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PRIORITY APPLN. INFO:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2006108689 | A2 | 20061019 | WO 2006-EP3480 | 20060406 |
| WO 2006108689 | A3 | 20070201 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DR, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MN, MX, NZ, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, RO, KZ, MD, RU, TJ, TM | | | | |
| AU 2006233736 | A1 | 20061019 | AU 2006-233736 | 20060406 |
| CA 2604397 | A1 | 20061019 | CA 2006-2604397 | 20060406 |
| EP 1869039 | A2 | 20071226 | EP 2006-724355 | 20060406 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR | | | | |
| PRIORITY APPLN. INFO: | | | GB 2005-7195 | A 20050408 |
| | | | WO 2006-EP3480 | W 20060406 |

OTHER SOURCE(S): MARPAT 145:438607

GI



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 491864-40-5 CAPLUS
 CN Benzonitrile,
 4-[2,3-dihydro-6-methyl-4-{3-(2-thiazolyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)



RN 491864-41-6 CAPLUS
 CN Benzonitrile,
 4-[2,3-dihydro-6-methyl-4-{3-(2-thiazolyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 AB A process for preparation of title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, alkyl, alkenyl, alkyanyl, haloalkyl, haloalkoxy, halo, amino, cyano; R2 = H, cycloalkyl, R9; R3 = cycloalkyl, R9; R5 = (substituted) alkyl; R2R3N = (substituted) 5-14 membered heterocycle] comprises treatment of (II; X = halo; R, R1 as above) with a Cu catalyst and a reactive derivative of the residue NR2R3. Thus, CuI and trans-N,N'-1,2-diaminocyclohexane were stirred together for 2-12 h in NMP; K2CO3, 2-(1H-pyrazol-3-yl)thiazole (preparation given), and


3-iodo-6-methyl-1-(2-methyl-4-(methoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (preparation given) in NMP were added followed by heating at 125° for 12-18 h to give 70% 6-methyl-1-(2-methyl-4-(methoxy)phenyl)-4-(3-(thiazol-2-yl)-1H-pyrazol-1-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine.

IT 912848-66-9
 RL IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclypyrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)

RN 912848-66-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-(5-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)



IT 491864-39-1P 491864-40-5P 491864-41-6P
 491864-42-7P 491864-46-1P 491865-57-7P
 491865-58-8P 491865-59-9P
 RL IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heterocyclypyrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine,


1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-

6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 491864-42-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-(2-methyl-4-(trifluoromethoxy)phenyl)-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 491864-46-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 491865-57-7 CAPLUS
 CN 1H-Pyrido[2,3-b]pyridine,
 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-
 6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-58-8 CAPLUS
 CN 1H-Pyrido[2,3-b]pyridine,
 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-
 6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-59-9 CAPLUS
 CN 1H-Pyrido[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-
 bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (CA INDEX NAME)




L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1093785 CAPLUS
 DOCUMENT NUMBER: 145:438617
 TITLE: Process for preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts.
 INVENTOR(S): Bacchi, Sergio; Delpogetto, Monica; Guelfi, Simone; Perboni, Alcide; Ribecai, Arianna; Stabile, Paolo; Tampieri, Marsia
 PATENT ASSIGNEE(S): SB Pharma Puerto Rico Inc, USA; Neurocrine Biosciences Inc
 SOURCE: PCT Int. Appl., 37pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2006108693 | A2 | 20061019 | WO 2006-EP3531 | 20060406 |
| WO 2006108693 | A3 | 20070705 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2006233740 | A1 | 20061019 | AU 2006-233740 | 20060406 |
| CA 2604384 | A1 | 20061019 | CA 2006-2604384 | 20060406 |
| EP 1874771 | A2 | 20080109 | EP 2006-724393 | 20060406 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| IN 2007DN07690 | A | 20071109 | IN 2007-DN7690 | 20071008 |
| KR 2008002937 | A | 20080104 | KR 2007-725907 | 20071107 |
| PRIORITY APPLN. INFO.: | | | GB 2005-7198 | A 20050408 |
| | | | WO 2006-EP3531 | W 20060406 |


OTHER SOURCE(S): MARPAT 145:438617
 GI




L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 AB Title compds. (I: R = (substituted) aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, thioalkyl, alkenyl, alkynyl, haloalkoxy, halo, amino, cyano; D = CRBR9, CR8; G = CR1OR11, CR1O; R8-R11 = H, cycloalkyl alkyl, alkenyl, alkynyl, amino, cyano; dotted line = optional double bond; Z = (substituted) heterocycl; W = (substituted) carbocycl in which 1 atom is replaced by CO, SOm, or 1-4 C atoms may be replaced by O, N, imino, CO, SOm, CO; m = 0-2), were prepared by treatment of (II; X = halo; R, R1 as above) with a reactive derivative of WZ (variables as above) catalyzed by Cu. Thus, CuI and trans-N,N'-dimethyl-1,2-diaminocyclohexane were stirred together in DMF for 2-12 h; K2CO3, 1-(1H-pyrazol-3-yl)-2-imidazolidinone (preparation given), and 3-bromo-6-methyl-1-(2-methyl-4-(methoxy)phenyl)-2,3-dihydropyrrolo[2,3-b]pyridine (preparation given) in DMF were added followed by heating at 125° for 36-42 h to give 70% 1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one.
 IT 491864-40-5P 491864-46-1P 786701-13-1P, 1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-15-3P, 1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridol[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-22-2P 786701-25-5P 786701-27-7P 786701-29-9P, 1-[1-(6-Methyl-1-[2-methyl-4-(trifluoromethyl)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]imidazolidin-2-one 786701-62-0P 786701-66-4P 786701-69-7P 786701-72-2P 786701-75-5P 786701-77-7P 786701-79-9P 786701-80-2P 786701-83-5P 912850-56-7P RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts); RN 491864-40-5 CAPLUS CN Benzonitrile, 4-(2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 491864-46-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 786701-13-1 CAPLUS
 CN 2-imidazolidinone,
 1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786701-15-3 CAPLUS
 CN 2-imidazolidinone,
 1-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-3-methyl- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-17-5 CAPLUS
 CN 2-Imidazolidinone, 1-(1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786701-22-2 CAPLUS
 CN 2-Imidazolidinone,
 1-acetyl-3-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-25-5 CAPLUS
 CN 2-Imidazolidinone,
 1-(1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786701-27-7 CAPLUS
 CN 2-Imidazolidinone, 1-(1-(2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)


L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-29-9 CAPLUS
 CN 2-Imidazolidinone, 1-(1-(2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786701-62-0 CAPLUS
 CN 2-Imidazolidinone,
 1-(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786701-66-4 CAPLUS
CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-69-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)




RN 786701-72-2 CAPLUS
CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-75-5 CAPLUS
CN 1,2,5-Thiadiazolidine-2-carboxylic acid,
5-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-methyl ester, 1,1-dioxide (CA INDEX NAME)




RN 786701-77-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine,
4-[3-(1,1-dioxido-2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 786701-79-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 786701-80-2 CAPLUS
CN 2(1H)-Pyridinone,
1-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 786701-83-5 CAPLUS
CN 2H-Imidazol-2-one,
1-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-1,3-dihydro- (CA INDEX NAME)




RN 912850-56-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrido[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004-927207 CAPLUS
DOCUMENT NUMBER: 141:395557
TITLE: Preparation of condensed heterocycles as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD
INVENTOR(S): Andreotti, Daniele; Bernasconi, Giovanni; Castiglioni, Emiliiano; Contini, Stefania; Di Fabio, Romano; Fazzolari, Elettra; Feriani, Aldo; Gentile, Gabrielle; Mattioli, Mario; Mingardi, Anna; Sabbatini, Fabio; St.-Denis, Yves
PATENT ASSIGNEE(S): SB Pharma Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
SOURCE: PCT Int. Appl., 129 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2004094420 | A1 | 20041104 | WO 2004-IB1350 | 20040407 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RN: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, C2, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004232551 | A1 | 20041104 | AU 2004-232551 | 20040407 |
| CA 2521929 | A1 | 20041104 | CA 2004-2521929 | 20040407 |
| EP 1611133 | A1 | 20060104 | EP 2004-726237 | 20040407 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, | | | | |
| HR | | | | |
| BR 2004009117 | A | 20060328 | BR 2004-9117 | 20040407 |
| CN 1805958 | A | 20060719 | CN 2004-80016189 | 20040407 |
| JP 2006522799 | T | 20061005 | JP 2006-506558 | 20040407 |
| IN 2005DN04455 | A | 20070831 | IN 2005-NA4455 | 20051003 |
| MX 2005PA10874 | A | 20060321 | MX 2005-PA10874 | 20051010 |
| NO 2005005238 | A | 20060109 | NO 2005-5238 | 20051108 |
| US 2007004708 | A1 | 20070104 | US 2006-552493 | 20060921 |
| PRIORITY APPLN. INFO.: | | | GB 2003-8208 | A 20030409 |
| US 2003-485322P | P | 20030707 | | |
| WO 2004-IB1350 | W | 20040407 | | |

OTHER SOURCE(S): MARPAT 141:395557
GI



AB Title [(pyrrolo[2,3-b]pyridinyl)pyrazolyl]imidazolidinones and related compds. I [wherein D = CR9R9, CR8; G = C10R11, CR10; W = (un)substituted carbocycl, heterocycl; X = C, N; Y = N, CR7; Z = (un)substituted heterocycl; Ph; R = (un)substituted (hetero)aryl; R1 = H, (cyclo)alkyl, (halo)alkoxy, alkylthio, alkenyl, halo(alkyl), halo, NR3R4, CN; R3, R4 = independently H, alkyl; R7 = H, (halo)alkyl, halo; R8-R11 = independently H, (cyclo)alkyl, alkenyl, alkynyl, NR3R4, CN; and stereoisomers, prodrugs and pharmaceutically acceptable salts, or solvates] thereof were prepared as corticotropin-releasing factor (CRF) antagonists.

For example, 4-iodo-6-methyl-1-[2-methyl-4-(methoxyphenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine was coupled with

1-(1H-pyrazol-3-yl)imidazolidin-2-one (preparation of reactants given) in the presence of CuI, K2CO3, dodecane, and trans-cyclohexanediamine in anh. NMP to afford II (53%). In binding assays using recombinant human CRF1 and CRF2 receptors expressed in CHO cell membranes, compds. of the invention showed affinity for CRF receptors

with Ki values of <10 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of depression, anxiety, IBS, and IBD (no data).

IT 786701-13-1P, 1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one (RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses))


(CRF antagonist; preparation of

(1-pyrrolypyridinyl)pyrazolyl]imidazolidinone

s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786701-13-1 CAPLUS

2-Imidazolidinone, 1-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)- (CA INDEX NAME)



IT 786701-15-3P, 1-[1-(1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-(1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-19-7P, 1-[1-(1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-20-OP, 1-[1-(1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-22-2P, 1-Acetyl-3-[1-(6-methyl-1-[2-methyl-4-

(methoxyphenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-25-5P, 1-[1-(1-(4-Ethoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-27-7P, 1-[1-(6-Methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-29-9P, 1-[1-(6-Methyl-1-[2-methyl-4-(trifluoromethyl)oxyphenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-31-3P, 3-Methyl-1-[6-methyl-1-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-34-6P, 1-[1-(6-Methyl-1-[2-methyl-4-(1H-pyrazol-3-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-35-7P, 4-(6-Methyl-1-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)benzonitrile 786701-37-9P, 1-[1-(2-

(difluoromethyl)-4-(methoxyphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-40-4P,

4-(6-Methyl-1-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)oxybenzonitrile 786701-43-7P, 3-Ethyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-44-8P, 1-[1-(6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-46-0P, 1-[1-(6-Methyl-1-[6-methyl-1,3-

benzodioxol-5-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-49-3P, 1-[1-(6-Methyl-1-[2,4,6-

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

tris(methoxy)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrrol-3-yl]-2-imidazolidinone 786701-57-3P,
 1-[1-[2,6-Dimethyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone
 786701-62-0P, 1-[5-Methyl-1-(5-methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-64-2P, 1-[1-(1-[4-(Difluoromethyl)oxy]-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-66-4P,
 1-[1-(1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-69-7P,
 1-[1-(1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-72-2P, 3-[1-(5-Methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone 786701-75-5P, 1-[1-(1,1-Dioxido-1,2,5-thiadiazolidin-5-yl)-1H-pyrazol-1-yl]-6-methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine
 786701-77-9P, 4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-80-2P, 3-Methyl-1-[1-(6-methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-2(1H)-pyridinone 786701-81-3P, 2-[1-(6-Methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-(2H)-pyridazinone 786701-83-5P, 1-[1-(6-Methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2(1H)-pyridinone 786701-84-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; prepn. of (pyrrolopyridinyl)pyrazolyl)imidazolidinone s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)


RN 786701-15-3 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl-

NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-17-7 CAPLUS
 CN 2-Imidazolidinone, 1-[1-(1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-19-7 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-(1-(2,4-bis(trifluoromethyl)phenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-20-0 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-22-2 CAPLUS
 CN 2-Imidazolidinone,
 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-25-5 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-(1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-27-7 CAPLUS
 CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(methoxymethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-29-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2-methyl-4-(trifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-31-3 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-1-(3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (CA INDEX NAME)




RN 786701-34-6 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(1H-pyrazol-1-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-35-7 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-1-(3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 786701-37-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-(1-(2-(difluoromethyl)-4-methoxyphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-40-4 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-1-(3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethoxy)- (CA INDEX NAME)




RN 786701-43-7 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-1-(3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-ethyl- (CA INDEX NAME)




RN 786701-44-8 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-1-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-46-0 CAPLUS
 CN 2-imidazolidinone, 1-[{2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-49-3 CAPLUS
 CN 2-imidazolidinone, 1-[{2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-57-3 CAPLUS
 CN 2-Imidazolidinone, 1-[{2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-62-0 CAPLUS
 CN 2-Imidazolidinone, 1-[{2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-5-methyl-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-64-2 CAPLUS
 CN 2-imidazolidinone, 1-[{1-[4-(difluoromethoxy)-2-methylphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-66-4 CAPLUS
 CN 2-Pyrrolidinone, 1-[{1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-69-7 CAPLUS
 CN 2-Pyrrolidinone, 1-[{2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)




RN 786701-72-2 CAPLUS
 CN 2-Oxazolidinone, 3-[{1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-75-5 CAPLUS
CN 1,2,5-Thiadiazolidine-2-carboxylic acid,
5-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1,1-dioxide (CA INDEX NAME)




RN 786701-77-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine,
4-(3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl)-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1,1-dioxide (CA INDEX NAME)




RN 786701-79-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-(3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl)-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1,1-dioxide (CA INDEX NAME)




RN 786701-80-2 CAPLUS
CN 2(1H)-Pyridinone,
1-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-3-methyl-1,1-dioxide (CA INDEX NAME)



RN 786701-81-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1,1-dioxide (CA INDEX NAME)



RN 786701-83-5 CAPLUS
CN 2H-Imidazol-2-one,
1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2,3-dihydro-1,1-dioxide (CA INDEX NAME)




IT 786700-23-OP, N-(1-[6-Methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)acetamide
786700-24-IP, 1-[6-Methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine
786700-25-2P 786700-26-3P, 2-[1-[6-Methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]carbamate 786700-29-6P,
1-(2-Diethoxyethyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]aminoethanol 786700-27-4P, 3-[1-(6-Methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]amino-1-propanesulfonic acid 786700-28-5P, Phenyl
[1-[6-Methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]carbamate 786700-29-6P,
1-(2-Diethoxyethyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]urea 786700-34-3P, 1-Acetyl-3-[1-(4-hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-35-4P, 1-Acetyl-3-[1-[1-(4-(ethoxy)-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-36-5P,
1-Acetyl-3-[1-(6-methyl-1-[2-methyl-4-(1-methylethyl)oxy]phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-37-6P, 1-(1-Methylethyl)-3-[1-(6-methyl-1-[2-methyl-4-(1-methylethyl)oxy]phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-48-9P,

1-(1-[6-Methyl-1-[2-methyl-4-(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[1-(4-methoxy)phenyl]methyl-2-imidazolidinone 786700-51-4P,
3-Methyl-4-[6-methyl-1-[3-[1-(4-methoxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-60-5P, 1-[1-[1-(2-Difluoromethyl)-4-(methoxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[1-(4-


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(methoxyphenyl)methyl]-2-imidazolidinone 786700-64-9P.

4-[6-Methyl-4-[(3-[(4-(methoxy)phenyl)methyl]-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-[(trifluoromethyl)oxy]benzonitrile 786700-67-2P,
3-Ethyl-4-[(6-methyl-4-[(4-(methoxy)phenyl)methyl]-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-ylbenzonitrile 786700-71-8P,
1-[1-(6-Methyl-1-[2-(methoxy)-4-(1H-pyrazol-1-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-(methoxy)phenyl)methyl]-2-imidazolidinone 786700-74-1P,
1-[(6-Methyl-1-[2-(methoxy)-4-(1H-pyrazol-1-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-(methoxy)phenyl)methyl]-2-imidazolidinone 786700-77-4P,
1-[(4-(Methoxy)phenyl)methyl]-1-methyl-1-[2,4,6-tris(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-81-0P,
1-[(1-(2,4-Bis(trifluoromethyl)phenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-(methoxy)phenyl)methyl]-2-imidazolidinone 786700-03-9P,
RN: 786700-23-0 CAPLUS
CN: Acetamide, N-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


RN: 786700-24-1 CAPLUS
CN: 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (CA INDEX NAME)




RN: 786700-28-5 CAPLUS
CN: Carbamic acid, [(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-phenyl ester (9CI) (CA INDEX NAME)




RN: 786700-29-6 CAPLUS
CN: Urea, N-(2,2-diethoxyethyl)-N'-(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN: 786700-34-3 CAPLUS
CN: 2-Imidazolidinone, 1-acetyl-3-[(1-(2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN: 786700-25-2 CAPLUS
CN: Glycine, N-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-ethyl ester (CA INDEX NAME)




RN: 786700-26-3 CAPLUS
CN: Ethanol, 2-[(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)




RN: 786700-27-4 CAPLUS
CN: 1-Propanesulfonic acid, 3-[(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN: 786700-34-3 CAPLUS
CN: 2-Imidazolidinone, 1-acetyl-3-[(1-(2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN: 786700-35-4 CAPLUS
CN: 2-Imidazolidinone, 1-acetyl-3-[(1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN: 786700-36-5 CAPLUS
CN: 2-Imidazolidinone, 1-acetyl-3-[(1-(2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 786700-37-6 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(1-methylethoxy)phenyl)-1H-pyrazol-1-yl)-1H-pyrazol-3-yl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 786700-40-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

PAGE 1-A





RN 786700-51-4 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrazolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)

PAGE 1-A




RN 786700-54-7 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-1H-pyrazolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

PAGE 1-A




RN 786700-57-0 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrazolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A

CF₃


PAGE 2-A

CHF₃


RN 786700-60-5 CAPLUS
 CN 2-imidazolidinone, 1-(1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

RN 786700-64-9 CAPLUS
 CN Benzonitrile, 4-[2,3-dihydro-4-{3-[(3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-(trifluoromethoxy)- (CA INDEX NAME)

PAGE 1-A

F₃C=O

PAGE 2-A




Et


RN 786700-67-2 CAPLUS
 CN Benzonitrile, 4-[2,3-dihydro-4-{3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (CA INDEX NAME)

RN 786700-71-8 CAPLUS
 CN 2-Imidazolidinone, 1-(1-[2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 1-A



PAGE 2-A




RN 786700-74-1 CAPLUS
 CN 2-imidazolidinone,
 1-(1-(2,3-dihydro-6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 786700-77-4 CAPLUS
 CN 2-Imidazolidinone, 1-(1-(2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-A



PAGE 2-A





RN 786700-81-0 CAPLUS
 CN 2-imidazolidinone,
 1-(1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

RN 786701-03-9 CAPLUS
 CN 2-Imidazolidinone, 1-(1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl)-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

|
CF₃

PAGE 1-A




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

PAGE 2-A

Me

RN 786701-09-5 CAPLUS
CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl- (CA INDEX NAME)



RN 786701-11-9 CAPLUS
CN 2-imidazolidinone, 1-acetyl-3-[1-(1-(4-(difluoromethoxy)-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610082 CAPLUS

DOCUMENT NUMBER: 141:157105

TITLE: Preparation of heteroaryl-substituted pyrrolo[2,3-b]pyridine derivatives as CRF receptor antagonists

INVENTOR(S): Castiglioni, Emiliano; Di Fabio, Romano; Feriani, Aldo; Micheli, Fabrizio; Sabbatini, Fabio; St-Denis, Yves

PATENT ASSIGNEE(S): SB Pharma Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004062665 | A1 | 20040729 | WO 2004-EP409 | 20040114 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, PE, PT, SI, TR, TW, US, VE, ZA | | | | |
| EP 1583531 | A1 | 20051012 | EP 2004-701955 | 20040114 |
| EP 1583531 | B1 | 20070418 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006515334 | T | 20060525 | JP 2006-500001 | 20040114 |
| AT 359782 | T | 20070515 | AT 2004-701955 | 20040114 |
| ES 2285409 | T3 | 20071116 | ES 2004-4701955 | 20040114 |
| US 2007066640 | A1 | 20070322 | US 2006-542196 | 20060303 |
| PRIORITY APPLN. INFO.: | | | US 2003-440432P | P 20030116 |
| | | | WO 2004-EP409 | W 20040114 |

OTHER SOURCE(S): MARPAT 141:157105
GI

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


AB Pyrrolo[2,3-b]pyridines of formula I ($R = \text{aryl, heteroaryl}; R1 = \text{H, cycloalkyl, alkyl, alkoxy, CN, etc.}; NR2R3 = (\text{substituted}) \text{ aromatic heterocycle}; R4 = \text{H, alkyl, halo, haloalkyl}$) are described, including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compns.

containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). Thus, II was prepared in several steps.


IT 727992-87-2P 727992-88-3P 727992-89-4P
727992-90-7P 727992-91-8P 727992-92-9P
727992-93-0P 727992-94-1P 727992-95-2P
727992-96-3P 727992-97-4P 727992-98-5P
727992-99-6P 727993-00-2P 727993-01-3P
727993-02-4P 727993-03-5P 727993-04-6P

727993-05-7P 727993-06-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)


RN 727992-87-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine,
2,3-dihydro-1-(6-methoxy-2-(trifluoromethyl)-3-pyridinyl)-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 727992-88-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine,
2,3-dihydro-1-(6-methoxy-2-methyl-3-pyridinyl)-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 727992-89-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-90-7 CAPLUS
CN 2-Pyridinamine, 5-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-N,N,4-trimethyl- (CA INDEX NAME)





RN 727992-91-8 CAPLUS




RN 727992-94-1 CAPLUS
CN Benzonitrile, 3-chloro-4-(2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl)- (CA INDEX NAME)



RN 727992-95-2 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (CA INDEX NAME)




RN 727992-92-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2-chloro-4-methoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-93-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,4-dimethoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)


RN 727992-96-3 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-ethyl- (CA INDEX NAME)




RN 727992-97-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(4-fluoro-2-methylphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-98-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-(2-methyl-4-(1H-pyrazol-1-yl)phenyl)-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-99-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-(4-nitro-2-(trifluoromethyl)phenyl)-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 727993-00-2 CAPLUS
CN Benzonitrile, 4-(4-(1,3'-bi-1H-pyrazol)-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (CA INDEX NAME)




RN 727993-01-3 CAPLUS
CN Benzonitrile, 4-(4-(1,3'-bi-1H-pyrazol)-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 727993-02-4 CAPLUS
CN Benzonitrile, 4-(4-(1,3'-bi-1H-pyrazol)-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-chloro- (CA INDEX NAME)




RN 727993-03-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-(1,3'-bi-1H-pyrazol)-1'-yl)-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 727993-04-6 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-4-(3-(2-pyridinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (CA INDEX NAME)




RN 727993-05-7 CAPLUS
CN Benzonitrile, 3-chloro-4-(2,3-dihydro-6-methyl-4-(3-(2-pyridinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)- (CA INDEX NAME)



RN 727993-06-8 CAPLUS
CN Benzonitrile, 4-(2,3-dihydro-6-methyl-4-(3-(2-pyridinyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



IT 491865-06-6
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)
 RN 491865-06-6 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 US 2004-483792 A1 20040114


OTHER SOURCE(S): MARPAT 138:137173
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines (I); wherein R = (substituted) aryl, heteroaryl; R1 = H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, halo(C1-C6)alkyl, halo(C1-C6)alkynyl, halogen, amino, or cyano; R2 = H, (C3-C7)cycloalkyl; R3 = (C3-C7)cycloalkyl; or R2 and R3 together with N form a (substituted) 5-14 membered heterocycle; R4 = H, (C1-C6)alkyl, halo, halo(C1-C6)alkyl; X = C, N; n = 1 or 2] were prepared. For example, compound (II) was prepared by the provided method. The prepared compds. are useful in the treatment of conditions mediated by corticotropin-releasing factor (CRF) (no data).

IT 491864-38-1P 491864-40-5P 491864-41-6P
 491864-42-7P 491864-46-1P 491865-57-7P
 491865-58-8P 491865-59-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)

RN 491864-38-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 491864-40-5 CAPLUS
 CN Benzonitrile,
 4-[2,3-dihydro-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 2003-76778 CAPLUS
 DOCUMENT NUMBER: 138:137173
 TITLE: Preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists
 INVENTOR(S): Di Fabio, Romano; Micheli, Fabrizio; St-denis, Yves
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2003008412 | A2 | 20030130 | WO 2002-EP7865 | 20020715 |
| WO 2003008412 | A3 | 20030501 | | |
| | | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, EA, EG, ES, GA, GE, GL, GR, IE, IT, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| GB 2378702 | A1 | 20030130 | GB 2002-16041 | 20020711 |
| CA 2451530 | A1 | 20030130 | CA 2002-2451530 | 20020715 |
| AU 2002328899 | A1 | 20030303 | AU 2002-328899 | 20020715 |
| EP 1425280 | A2 | 20040609 | EP 2002-764696 | 20020715 |
| EP 1425280 | B1 | 20060830 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002011171 | A | 20040810 | BR 2002-11171 | 20020715 |
| CN 1525972 | A | 20040901 | CN 2002-813866 | 20020715 |
| HU 2004000465 | A2 | 20050128 | HU 2004-465 | 20020715 |
| JP 2005514328 | T | 20050519 | JP 2003-513971 | 20020715 |
| NZ 530043 | A | 20060331 | NZ 2002-530043 | 20020715 |
| EP 1695974 | A1 | 20060830 | EP 2006-76176 | 20020715 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR, BG, CZ, EE, SK | | | | |
| AT 338042 | T | 20060915 | AT 2002-764696 | 20020715 |
| ES 2271327 | T3 | 20070416 | ES 2002-2764696 | 20020715 |
| RU 2310655 | C2 | 20071120 | RU 2004-104349 | 20020715 |
| IN 2003DN02137 | A | 20070302 | IN 2003-DN2137 | 20031209 |
| ZA 2003009708 | A | 20050121 | ZA 2003-9708 | 20031215 |
| US 2004171607 | A1 | 20040902 | US 2004-483792 | 20040114 |
| US 7253284 | B2 | 20070807 | | |
| NO 2004000206 | A | 20040316 | NO 2004-206 | 20040116 |
| MX 2004PA00494 | A | 20040504 | MX 2004-PA494 | 20040116 |
| HK 1066535 | A1 | 20070309 | HK 2004-109443 | 20041130 |
| US 2007219232 | A1 | 20070920 | US 2007-749433 | 20070516 |
| PRIORITY APPLN. INFO.: | | | GB 2001-17396 | A 20010717 |
| | | | EP 2002-764696 | A3 20020715 |
| | | | WO 2002-EP7865 | W 20020715 |


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 491864-41-6 CAPLUS
 CN Benzonitrile,
 4-(2,3-dihydro-6-methyl-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 491864-42-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-(3-(2-thiazolyl)-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 491864-46-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491865-57-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-58-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491865-59-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (CA INDEX NAME)



IT 491865-06-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolyl-pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)

RN 491865-06-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 18:24:28 ON 30 JAN 2008)

FILE 'REGISTRY' ENTERED AT 18:24:38 ON 30 JAN 2008

L1 STRUCTURE UPLOADED
L2 4 S L1
L3 86 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:25:17 ON 30 JAN 2008

L4 5 S L3 FULL

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 27.73 | 206.30 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | -4.00 | -4.00 |

STN INTERNATIONAL LOGOFF AT 18:26:06 ON 30 JAN 2008

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|------|-------------------------|---|------------------|---------|------------------|
| L1 | 1783 | (514/300,546/113).CCLS. | US-PGPUB;
USPAT;
USOCR;
EPO; JPO;
DERWENT | OR | OFF | 2008/01/30 18:35 |
| L2 | 774 | I1 and bicyclic | US-PGPUB;
USPAT;
USOCR;
EPO; JPO;
DERWENT | OR | OFF | 2008/01/30 18:36 |
| L3 | 254 | I2 and imidazol | US-PGPUB;
USPAT;
USOCR;
EPO; JPO;
DERWENT | OR | OFF | 2008/01/30 18:38 |
| L4 | 194 | I3 and pyridin | US-PGPUB;
USPAT;
USOCR;
EPO; JPO;
DERWENT | OR | OFF | 2008/01/30 18:39 |
| L5 | 54 | I4 and pyrrolo | US-PGPUB;
USPAT;
USOCR;
EPO; JPO;
DERWENT | OR | OFF | 2008/01/30 18:39 |